RxDoctor Payments Data

Jinal Gangar, MD

Family Medicine · Easton, PANPI 1245618164

Payments from drug & device makers

$3,676in general payments, 2019–2025

Across 178 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$437
  • Pfizer$389
  • GSK$384
  • Esperion Therapeutics, Inc.$227
  • Boehringer Ingelheim$221
  • Merck$207
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,36692%
  • Education$3098%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,676 in reported general payments places this provider in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$67,862
Medicare patients
129
Services billed
1,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$53,439
EliquisApixaban77$52,904
TrulicityDulaglutide30$49,914
OzempicSemaglutide28$43,049
FarxigaDapagliflozin Propanediol13$19,679
XareltoRivaroxaban20$17,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,242
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,761
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate32$6,722
Albuterol Sulfate HfaAlbuterol Sulfate198$5,030
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,529
Atorvastatin Calcium207$2,057
Acarbose31$1,291
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic17$1,225
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$221$53,43940 claims
PfizerEliquis$389$52,90477 claims
Lilly USA, LLCTrulicity$158$49,91430 claims
Novo NordiskOzempic$188$43,04928 claims
AstraZenecaFarxiga, Breztri Aerosphere$437$28,44027 claims
Johnson & JohnsonXarelto$27$17,08720 claims
GSKTrelegy Ellipta$384$10,24216 claims
AbbVieSynthroid$124$65713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Easton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →